Abstract
Gene-directed enzyme prodrug therapy (GDEPT) consists in targeted delivery to tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. One of the major limitations of this strategy in clinical application was the poor prodrug activation capacity of suicide gene. We built a highly efficient suicide gene capable of bioactivating the prodrug cyclophosphamide (CPA) by fusing a CYP2B6 triple mutant with NADPH cytochrome P450 reductase (CYP2B6TM-RED). Expression of this fusion gene via a recombinant lentivirus (LV) vector converted resistant human (A549) and murine (TC1) pulmonary cell lines into CPA-susceptible cell lines. We tested the efficiency of our GDEPT strategy in C57Bl/6 immunocompetent mice, using TC1 cells expressing the HPV-16 E6/E7 oncoproteins. In mice bearing tumors composed only of TC1-CYP2B6TM-RED cells, four CPA injections (140 mg/Kg once a week) completely eradicated the tumors for more than two months. Tumors having only 25% of TC1-CYP2B6TM-RED cells were also completely eradicated by five CPA injections, demonstrating a major in vivo bystander effect. Moreover, surviving mice were rechallenged with parental TC1 cells. The tumors regressed spontaneously 7 days after cell inoculation or grew more slowly than in control naive mice due to a strong immune response mediated by anti-E7CD8+T cells. These data suggest that combining the CYPB6TM-RED gene with CPA may hold promise as a highly effective treatment for solid tumors in humans.
Keywords: Cytochrome P450 2B6, lentivirus, cyclophosphamide, lung cancer.
Current Gene Therapy
Title:A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Volume: 14 Issue: 3
Author(s): Walid Touati, Thi Tran, Johanne Seguin, Monique Diry, Jean-Pierre Flinois, Claude Baillou, Geraldine Lescaille, Francois Andre, Eric Tartour, Francois M. Lemoine, Philippe Beaune and Isabelle de Waziers
Affiliation:
Keywords: Cytochrome P450 2B6, lentivirus, cyclophosphamide, lung cancer.
Abstract: Gene-directed enzyme prodrug therapy (GDEPT) consists in targeted delivery to tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. One of the major limitations of this strategy in clinical application was the poor prodrug activation capacity of suicide gene. We built a highly efficient suicide gene capable of bioactivating the prodrug cyclophosphamide (CPA) by fusing a CYP2B6 triple mutant with NADPH cytochrome P450 reductase (CYP2B6TM-RED). Expression of this fusion gene via a recombinant lentivirus (LV) vector converted resistant human (A549) and murine (TC1) pulmonary cell lines into CPA-susceptible cell lines. We tested the efficiency of our GDEPT strategy in C57Bl/6 immunocompetent mice, using TC1 cells expressing the HPV-16 E6/E7 oncoproteins. In mice bearing tumors composed only of TC1-CYP2B6TM-RED cells, four CPA injections (140 mg/Kg once a week) completely eradicated the tumors for more than two months. Tumors having only 25% of TC1-CYP2B6TM-RED cells were also completely eradicated by five CPA injections, demonstrating a major in vivo bystander effect. Moreover, surviving mice were rechallenged with parental TC1 cells. The tumors regressed spontaneously 7 days after cell inoculation or grew more slowly than in control naive mice due to a strong immune response mediated by anti-E7CD8+T cells. These data suggest that combining the CYPB6TM-RED gene with CPA may hold promise as a highly effective treatment for solid tumors in humans.
Export Options
About this article
Cite this article as:
Touati Walid, Tran Thi, Seguin Johanne, Diry Monique, Flinois Jean-Pierre, Baillou Claude, Lescaille Geraldine, Andre Francois, Tartour Eric, Lemoine M. Francois, Beaune Philippe and Waziers de Isabelle, A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response, Current Gene Therapy 2014; 14 (3) . https://dx.doi.org/10.2174/1566523214666140424152734
DOI https://dx.doi.org/10.2174/1566523214666140424152734 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, further converted to melatonin by ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer
Current Signal Transduction Therapy The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design An Artificial Neural Network Model for Predicting the Subcellular Localization of Photosensitisers for Photodynamic Therapy of Solid Tumours
Current Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism Nanofibers: An Effective Tool for Controlled and Sustained Drug Delivery
Current Drug Delivery Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review
Current Medical Imaging Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Separation and Identification of Antibacterial Chamomile Components Using OPLC, Bioautography and GC-MS
Medicinal Chemistry Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Telomeric G-Quadruplex Architecture and Interactions with Potential Drugs
Current Pharmaceutical Design Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Radiation and Gene Therapy: Rays of Hope for the New Millennium?
Current Gene Therapy Osthole: A Medicinally Privileged Natural Compound with its Therapeutic Potential
The Natural Products Journal